MedElevator
Войти в исследования Frontiers in cardiovascular medicine · 2026
Long-term follow-up results of percutaneous closure of atrial septal defect with a novel biodegradable poly-L-lactic acid device in pediatrics: data from a prospective, single-center trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yi-Fan, Xie Zhao-Feng, Li Bo-Ning, Shen Jun-Jun, Wang Shu-Shui, Xie Yu-Mei, Zhang Zhi-Wei
Аннотация
BACKGROUND: The poly-L-lactic acid (PLLA) occluder is a novel, fully biodegradable device designed for percutaneous atrial septal defect (ASD) closure. First-in-human studies have demonstrated its preliminary safety and efficacy.
OBJECTIVE: This study aimed to evaluate the 5-year safety and efficacy of the PLLA device for percutaneous ASD closure in a single-center pediatric cohort.
METHODS: From May 2018 to August 2019, 36 patients with clinically significant ASD were enrolled and underwent percutaneous closure using the PLLA device. Follow-up assessments were conducted at discharge and at 1, 3, 6, 12, 24, 36, 48, and 60 months post-implantation. The primary endpoint was a composite of clinical success, defined as successful closure and absence of major complications at the 60-month follow-up.
RESULTS: Successful device implantation was achieved in 35 of 36 patients (97.2%). All of the 35 patients completed the 5-year follow-up. The closure success rate and complete closure rate at 5 years were 85.7% (30/35) and 77.1% (27/35), respectively. Clinically significant residual leaks at 5- year visit were observed in 5 patients (14.3%). A total of 5 complications (14.3%) occurred, consisting of cardiac arrhythmia (n = 3), moderate mitral regurgitation (n = 1), and migraine (n = 1). Patients with a larger baseline ASD indexed diameter (>15.18 mm/m2) and a smaller device-to-defect ratio (<1.47) showed an increased risk of residual leaks after PLLA device implantation.
CONCLUSION: Long-term follow-up confirms a favorable safety profile for percutaneous ASD closure using the PLLA device, with a cumulative complication rate of 14.2% and no major adverse events reported over 5 years. However, the incidence of residual leaks remains noteworthy, suggesting suboptimal long-term efficacy in pediatric patients and in cases involving large defects.
OBJECTIVE: This study aimed to evaluate the 5-year safety and efficacy of the PLLA device for percutaneous ASD closure in a single-center pediatric cohort.
METHODS: From May 2018 to August 2019, 36 patients with clinically significant ASD were enrolled and underwent percutaneous closure using the PLLA device. Follow-up assessments were conducted at discharge and at 1, 3, 6, 12, 24, 36, 48, and 60 months post-implantation. The primary endpoint was a composite of clinical success, defined as successful closure and absence of major complications at the 60-month follow-up.
RESULTS: Successful device implantation was achieved in 35 of 36 patients (97.2%). All of the 35 patients completed the 5-year follow-up. The closure success rate and complete closure rate at 5 years were 85.7% (30/35) and 77.1% (27/35), respectively. Clinically significant residual leaks at 5- year visit were observed in 5 patients (14.3%). A total of 5 complications (14.3%) occurred, consisting of cardiac arrhythmia (n = 3), moderate mitral regurgitation (n = 1), and migraine (n = 1). Patients with a larger baseline ASD indexed diameter (>15.18 mm/m2) and a smaller device-to-defect ratio (<1.47) showed an increased risk of residual leaks after PLLA device implantation.
CONCLUSION: Long-term follow-up confirms a favorable safety profile for percutaneous ASD closure using the PLLA device, with a cumulative complication rate of 14.2% and no major adverse events reported over 5 years. However, the incidence of residual leaks remains noteworthy, suggesting suboptimal long-term efficacy in pediatric patients and in cases involving large defects.